

Sixth Annual Report on Schizophrenia Pharmacotherapy in VA

FY 2004

Douglas L. Leslie, Ph.D. and Robert Rosenheck, M.D.

Northeast Program Evaluation Center, West Haven VAMC; VA Connecticut Mental Illness Research, Education and Clinical Center; VA Connecticut Clinical Epidemiology Research Center; and the Departments of Psychiatry and Epidemiology/Public Health, Yale School of Medicine, New Haven, CT

Address correspondence to:

Douglas L. Leslie, Ph.D.
NEPEC/182
950 Campbell Ave.
West Haven, CT 06516

Abstract

Background: Pharmacotherapy is the cornerstone of effective treatment for schizophrenia. This report presents a profile of the use of antipsychotic medications in the treatment of schizophrenia in the Department of Veterans Affairs nationwide.

Methods: Patients were identified as being diagnosed with schizophrenia if they had at least two outpatient encounters with a diagnosis of schizophrenia during fiscal year (FY) 2004. All VA prescription drug records for antipsychotic medications written during FY 2004 were then collected for these patients. Patients who received a prescription for an antipsychotic medication were identified. Taking the last antipsychotic prescription during this period and going back seven days, all antipsychotic medications that were prescribed and the amount prescribed for each patient receiving an antipsychotic were identified. Measures of polypharmacy and compliance with PORT recommendations were constructed from these data, as well as indicators reflecting the use of atypical antipsychotics, and compared with the values from FY 2003.

Results: Of the 92,064 patients in the final sample with schizophrenia, 77,504 received at least one prescription for an antipsychotic medication (84.2%). Of these patients, 6,916 (8.9%) met criteria for polypharmacy, which is an increase of 0.5% from FY 2003. The majority of patients (49,658 or 64.1%) were dosed within the PORT recommended range, while 9,727 (12.6%) were dosed above the PORT recommendations, a decrease of 0.2% from the FY 2003 level. Of the patients who received atypical antipsychotics (63,420 or 81.8%), most received either risperidone (23,433 or 36.9%) or olanzapine (20,104 or 31.7%). Slightly fewer patients received quetiapine (14,802 or 23.3%), and far fewer

received ziprasidone (3,630 or 5.7%), aripiprazole (2,230 or 3.5%) or clozapine (1,865 or 2.9%). Compared to FY 1999 levels, the first year for which these data are available, there has been a dramatic shift from conventional to atypical antipsychotic medications.

Conclusions: The proportion of patients who were dosed within the PORT recommended range in FY 2004 remained fairly constant compared to the FY 2003 level. However, the percentage of patients dosed above the recommendations decreased by 2.8% and the proportion dosed below the recommendations increased by 2.4%. The proportion of patients receiving more than one antipsychotic medication increased slightly to 8.9%. The number of outpatients diagnosed with schizophrenia who received an atypical antipsychotic is leveling off over time, although the use of quetiapine and aripiprazole has grown while fewer patients were prescribed olanzapine.

I. Introduction

Pharmacotherapy has long been the cornerstone of treatment for schizophrenia. As health care systems respond to pressures to reduce the costs of care, there is a growing concern that quality be systematically monitored and preserved. Performance assessment based on clinically derived practice guidelines provides one mechanism for evaluating the quality of care in a clinical practice or organization. The Schizophrenia Patient Outcomes Research Team (PORT) has developed one widely respected set of guidelines for the treatment of schizophrenia (1).

The Veterans Health Administration of the Department of Veteran Affairs (VA) has not been immune to pressures to reduce health care costs. In 1995, VA experienced a major reorganization in which 22 distinct geographically based Veterans Integrated Service Networks (VISNs) were created, each responsible for the veteran population within its boundaries. An associated goal of the reorganization was to shift the focus of care away from acute inpatient care and towards more ambulatory and primary care in order to improve the accessibility of services and to address anticipated budget reductions (2). Between 1995 and 1999, total mental health expenditures declined by 13%, even without adjustment for inflation (3).

Pharmacologic treatment of schizophrenia has changed in recent years with the introduction of newer atypical antipsychotic medications. These medications (i.e. clozapine, olanzapine, risperidone, quetiapine, and, most recently, ziprasidone and aripiprazole) are considered to be equally or more effective than conventional antipsychotic medications and to have substantially superior side effect profiles.

However, these medications are considerably more expensive than conventionals, with annual costs averaging \$3,000 - \$5,000, 10 times the \$300 average annual cost of treatment with haloperidol.

As part of an ongoing effort to monitor quality of mental health care in VA (4-7), this report serves three functions: 1) it examines the extent to which pharmacotherapeutic care for patients diagnosed with schizophrenia conforms to the schizophrenia PORT treatment guidelines, 2) it investigates the availability of atypical antipsychotics to patients in VA, and 3) it tracks changes over time in these aspects of pharmacotherapeutic care for schizophrenia.

II. Methods

Sources of data

Data for the study come from national VA administrative databases. First, all VA outpatients diagnosed with schizophrenia during fiscal year (FY) 2004 (October 1, 2003 to September 30, 2004) were identified. Patients were identified as being diagnosed with schizophrenia if they had at least two outpatient encounters in a specialty mental health outpatient clinic with a primary or secondary diagnosis of schizophrenia (ICD-9 codes 295.00 – 295.99). The outpatient encounter file, a national database of information concerning all outpatient clinic stops in VA, was used to identify these patients. Next, all outpatient prescription drug records for these patients during FY 2004 were collected from the Decision Support System (DSS) Pharmacy file for FY 2004.

Measures

First, for each patient who received a prescription for an antipsychotic medication, the last prescription for an antipsychotic medication filled in FY 2004 was identified as the index prescription. All prescriptions for antipsychotic medications written during the 7 days prior to the index prescription were then identified. Next, chlorpromazine (CPZ) equivalents were calculated for each prescription for a conventional antipsychotic medication based on the updated PORT dosing algorithms (A. Lehmann, personal communication). CPZ equivalents were summed over all conventional antipsychotic prescriptions during the week to assess guideline adherence. If the total daily CPZ equivalent for all conventional antipsychotics prescribed during the week was greater than the PORT recommendation (1000 mg), the patient was identified as being dosed too high. For the atypical antipsychotics, the total daily dosage for each medication prescribed during the week was calculated. If the total dosage of any atypical was greater than the recommended range, the patient was identified as being dosed too high.¹ In addition, a patient was also identified as being dosed too high if they were prescribed the maximum recommended dose of one atypical *and* were also prescribed any amount of a second atypical.

¹ The maximum PORT recommended dose for atypical antipsychotic medications are as follows: clozapine 600 mg/day, olanzapine 20 mg/day, quetiapine 450 mg/day and risperidone 6 mg/day. For ziprasidone and aripiprazole, the maximum recommended dose was obtained from the product labels for these drugs (160 mg/day and 30 mg/day, respectively).

Although prescribing multiple antipsychotic medications is not addressed in the PORT guidelines, polypharmacy generally is not recommended for schizophrenia patients because additional medications may exacerbate side effects while doing little to alleviate symptoms (8, 9). Patients who were prescribed more than one antipsychotic medication during the week were identified as receiving polypharmacy. In addition, the subgroup of patients whose polypharmacy consisted of receiving both an atypical and a conventional antipsychotic medication was examined.

Analysis

Data analysis proceeded in several steps. First, the proportion of patients with the following characteristics were determined: 1) those who received multiple antipsychotic medications, 2) those whose dose was within the PORT recommended range, 3) those who were dosed above the PORT recommendation with any medication, 4) those who were dosed above the PORT recommendation with a conventional antipsychotic, 5) those who were dosed above the PORT recommendation with an atypical antipsychotic, 6) those who received any atypical antipsychotic, and 7) through 12) those who received the specific atypical antipsychotic medications clozapine, olanzapine, quetiapine, risperidone, ziprasidone or aripiprazole among patients receiving any atypical. Means of these measures were calculated by station and by VISN, as well as the percent change from their FY 2003 levels.

III. Results

Table 1 shows characteristics of the sample. Of the 92,064 patients diagnosed with schizophrenia during FY 2004 who received their medications from VA pharmacies,

77,504 (84.2%) received an antipsychotic medication. Very few patients were treated with multiple antipsychotic medications (8.9%). A higher proportion (12.6%) was prescribed a dose that was higher than the recommended range, with most of these patients being dosed too high on an atypical antipsychotic medication. The majority (81.8%) of patients received an atypical antipsychotic. This is a slightly smaller percentage than seen in FY 2003, although it represents an increase of 23.0% from the FY 1999 figure, the first year that these data were available (Figure 1). Among patients prescribed an atypical, most received either risperidone (36.9%) or olanzapine (31.7%), with a smaller proportion receiving quetiapine (23.3%), and much smaller proportions receiving ziprasidone (5.7%), aripiprazole (3.5%), or clozapine (2.9%).

Tables 2 and 3 report pharmacy measures at the level of the VISN and the facility, respectively. The coefficient of variation at the bottom of each table indicates the amount of variation among VISNs and facilities. At both the VISN level and the facility level, variation was relatively high for the percentage of patients prescribed clozapine or aripiprazole. Variation was small for the percentage of patients prescribed any antipsychotic medication, the percentage of patients prescribed an atypical, and the percentage of patients dosed within the PORT recommended range.

IV. Discussion

This study profiled pharmacologic treatment of patients with schizophrenia in VA. The proportion of patients who were treated with more than one antipsychotic medication, who were dosed above the schizophrenia PORT recommended dosage, and who were prescribed an atypical antipsychotic medication were determined. Only a

small proportion (8.9%) of patients were prescribed multiple antipsychotic treatment regimens, while a higher percentage (12.6%) were dosed above PORT guidelines. A majority of patients (81.8%) were prescribed an atypical antipsychotic, most often olanzapine or risperidone.

In previous work, we performed logistic regressions to explore the effects of patient and facility characteristics on the likelihood that patients with a diagnosis of schizophrenia who are prescribed an antipsychotic received an atypical medication, were dosed outside of the PORT recommended range or were prescribed polypharmacy (10-12). We found that older patients, Blacks and patients with a service connected disability were generally less likely to be prescribed an atypical, while patients with a comorbid mental health diagnosis were more likely to receive these medications. Older patients and those with a comorbid mental health diagnosis were less likely to be dosed above PORT guidelines, and older patients and Blacks were less likely to be prescribed multiple antipsychotic medications. The facility characteristics that we included in our models, which included measures of academic emphasis, reliance on inpatient care and fiscal stress, were generally not significant predictors of our quality measures.

A limitation of the analyses presented in this report relates to the difficulty in measuring prescribing patterns using administrative prescription data. Prescriptions may last for varying lengths of time. Patients with multiple prescriptions may run out of their medications and need to see their doctor to refill their prescriptions at different times. We collect all prescription drug records during a one-week period, but a longer time frame may be necessary to identify all of the drugs a particular patient is taking. Hence,

our measures of polypharmacy or whether a patient is dosed above PORT guidelines may be underestimated.

While the proportions of patients diagnosed with schizophrenia who are prescribed multiple antipsychotic medications or who are prescribed a dose that exceeds PORT recommended range are fairly small, these phenomena are still a concern. These medications are studied extensively before they are approved for use, but trials typically do not include combinations with other antipsychotics or abnormally high doses. Hence, the effects of these treatment regimens are unknown. More research is needed to investigate why physicians are prescribing in this manner.

References

1. Lehman AF, Steinwachs DM, the Co-Investigators of the PORT Project:
Translating Research into Practice: The Schizophrenia Patient Outcomes
Research Team (PORT) Treatment Recommendations. Schizophrenia Bulletin
1998; 24(1):1-10
2. Rosenheck R, Horvath T: The Impact of VA Reorganization on Patterns of
Mental Health Care. Psychiatric Services 1998; 49:53
3. Rosenheck RA, DiLella D: Department of Veterans Affairs National Mental
Health Program Performance Monitoring System: Fiscal Year 1999 Report. West
Haven, CT, Northeast Program Evaluation Center, 2000
4. Chen RS, Nadkarni PM, Levin FL, Miller PL, Erdos J, Rosenheck RA: Using a
Computerized Hospital Database to Monitor Compliance of Pharmacotherapeutic
Guidelines in the Treatment of Schizophrenia. Psychiatric Services 2000;
51(6):791-4
5. Leslie DL, Rosenheck RA: Comparing Quality of Mental Health Care in Public
Sector and Privately Insured Populations: First Efforts and Methodological
Challenges. Psychiatric Services 2000; 51(5):650-5
6. Rosenheck RA, Cicchetti D: A Mental Health Program Report Card: A
Multidimensional Approach to Performance Monitoring in Public Sector
Programs. Community Mental Health Journal 1998; 34(1):85-106

7. Rosenheck RA, Fontana A, Stolar M: Assessing Quality of Care: Administrative Indicators and Clinical Outcome Measures. *Medical Care* 1999; 37(2):180-188
8. Stahl SM: Antipsychotic Polypharmacy, Part 1: Therapeutic Option or Dirty Little Secret? *Journal of Clinical Psychiatry* 1999; 60(7):425-6
9. Stahl SM: Antipsychotic Polypharmacy, Part 2: Tips on Use and Misuse. *Journal of Clinical Psychiatry* 1999; 60(8):506-7
10. Leslie DL, Rosenheck RA: Pharmacotherapeutic Treatment of Schizophrenia in the Department of Veterans Affairs: Prescribing Patterns and Guideline Adherence. West Haven, CT, Northeast Program Evaluation Center, 2000, pp 1-19
11. Leslie D, Rosenheck R: The Effects of Institutional Fiscal Stress on the Use of Atypical Antipsychotic Medications in the Treatment of Schizophrenia. *The Journal of Nervous and Mental Disease* 2001; 189(6): 377-383
12. Leslie D, Rosenheck R: Use of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System: Individual and Facility Predictors. *Medical Care* 2001; 39(9): 923-933

Table 1. Sample characteristics

Variable	FY 2004		Change from FY 2003	Change from FY 1999
	N	%		
All patients	92,064	100.0%	N/A *	-10.6% ***
Prescribed any antipsychotic	77,504	84.2%	N/A *	3.3% ***
Polypharmacy	6,916	8.9%	0.5%	2.1%
Receiving both atypical and conventional	3,726	4.8%	0.1%	-0.4%
Dose within PORT guidelines	49,658	64.1%	0.2%	N/A
Dose higher than PORT guidelines	9,727	12.6%	-2.8%	-2.1%
Conventional antipsychotics	1,680	2.2%	0.4%	-9.0%
Atypical antipsychotics	8,169	10.5%	-3.2%	1.8%
Dose lower than PORT guidelines	18,404	23.7%	2.4%	-5.1% ***
Conventional antipsychotics	9,112	11.8%	0.3%	-10.1% ***
Atypical antipsychotics	8,169	10.5%	0.4%	3.3% ***
Received any conventional antipsychotic	17,810	23.0%	0.8%	-23.5%
Received any atypical antipsychotic	63,420	81.8%	-0.7%	23.0%
Clozapine	1,865	2.9%	-0.3%	-2.2%
Olanzapine	20,104	31.7%	-4.9%	-16.7%
Quetiapine	14,802	23.3%	2.1%	19.1%
Risperadone	23,433	36.9%	-0.4%	-6.9%
Ziprasidone	3,630	5.7%	0.9%	N/A **
Aripiprazole	2,230	3.5%	2.2%	N/A **

* These data were not available for FY 2003.

** Aripiprazole was new to the market in FY 2003. No patients received this drug before FY 2003. Ziprasidone was approved for use in 2001. No patients received this drug in FY 1999.

*** Figures from FY 1999 not available. Figures from FY 2000 used instead.

Figure 1. The Percentage of Patients Prescribed Atypical Antipsychotic Medications




Table 2a. VISN-level pharmacy measures -- Fiscal Year 2004

VISN	N	Percent prescribed any antipsychotic		Percent with polypharmacy in past week		Percent dosed within PORT recommended range		Percent dosed higher than PORT recommended range		Percent dosed high on conventionals		Percent dosed high on atypicals		Percent dosed lower than PORT recommended range		Percent dosed low on conventionals		Percent dosed low on atypicals	
		Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from	
		FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003
1	4,534	81.7%	N/A	11.8%	-1.0%	60.6%	0.9%	13.1%	-4.8%	7.6%	1.6%	14.1%	-5.8%	26.6%	3.5%	57.4%	2.7%	16.7%	2.7%
2	2,518	83.7%	N/A	10.3%	0.9%	59.6%	2.4%	15.2%	-1.4%	6.2%	-1.0%	17.6%	-1.4%	25.7%	-1.2%	57.4%	0.8%	13.7%	-1.8%
3	5,050	82.6%	N/A	10.9%	1.6%	63.3%	-0.3%	12.7%	-1.9%	9.1%	0.4%	13.2%	-2.8%	24.3%	2.0%	49.3%	0.7%	13.7%	2.0%
4	5,693	84.8%	N/A	9.5%	0.4%	61.4%	0.5%	10.6%	-3.2%	8.5%	1.6%	10.7%	-5.0%	28.3%	2.4%	53.4%	-0.3%	17.0%	3.5%
5	2,675	83.4%	N/A	11.1%	1.3%	66.5%	2.9%	12.1%	-6.6%	10.7%	-1.0%	11.6%	-7.7%	21.7%	3.7%	47.1%	3.1%	15.1%	3.3%
6	4,028	85.6%	N/A	8.0%	1.8%	63.4%	-0.6%	12.4%	-1.6%	10.8%	2.1%	12.3%	-2.9%	24.4%	2.0%	49.2%	-2.2%	14.8%	3.0%
7	6,091	85.6%	N/A	7.2%	0.4%	65.8%	-1.5%	11.2%	-2.1%	8.2%	0.3%	11.4%	-2.7%	23.4%	3.5%	50.5%	-0.5%	16.4%	4.5%
8	9,117	83.2%	N/A	6.5%	0.9%	61.6%	-2.6%	12.1%	0.2%	14.2%	7.1%	11.2%	-1.6%	26.5%	2.4%	52.3%	-2.3%	18.5%	3.3%
9	3,382	83.6%	N/A	6.8%	-0.3%	63.9%	0.2%	9.9%	-3.5%	6.1%	-1.2%	10.8%	-4.2%	26.4%	3.2%	51.5%	2.1%	17.3%	4.0%
10	4,422	82.0%	N/A	7.7%	-0.9%	63.4%	1.2%	11.9%	-4.1%	11.4%	4.4%	11.4%	-6.2%	25.1%	2.7%	50.8%	-2.9%	15.6%	3.1%
11	4,666	87.2%	N/A	9.2%	0.8%	64.1%	0.4%	16.0%	-2.2%	14.4%	1.5%	15.6%	-3.2%	20.4%	1.7%	43.7%	-1.2%	11.8%	2.0%
12	3,694	83.2%	N/A	9.0%	1.2%	67.3%	0.1%	10.6%	-1.3%	7.8%	2.5%	10.9%	-2.1%	22.7%	1.3%	52.6%	0.5%	14.4%	1.1%
15	3,901	86.9%	N/A	12.7%	1.6%	64.1%	1.5%	13.5%	-3.9%	9.9%	1.0%	13.7%	-5.0%	23.0%	2.3%	48.7%	-1.0%	13.5%	2.6%
16	7,776	85.9%	N/A	8.9%	0.1%	66.0%	-0.1%	12.6%	-3.7%	8.3%	-1.1%	13.3%	-3.9%	21.9%	3.7%	48.7%	1.2%	14.2%	3.2%
17	3,688	83.3%	N/A	7.8%	-0.9%	67.5%	2.2%	13.8%	-4.9%	8.7%	1.1%	14.3%	-5.9%	19.0%	2.5%	49.1%	-2.3%	12.9%	3.4%
18	2,739	79.0%	N/A	6.3%	0.1%	66.7%	1.0%	7.8%	-2.8%	5.0%	0.6%	8.2%	-3.6%	25.8%	1.8%	62.4%	2.8%	15.9%	1.3%
19	2,049	87.0%	N/A	11.3%	1.1%	63.0%	-0.3%	12.7%	-3.0%	5.5%	-0.4%	13.9%	-3.4%	25.0%	3.1%	51.6%	-4.4%	16.7%	4.8%
20	3,528	85.5%	N/A	7.6%	0.5%	64.5%	-0.7%	14.2%	-0.8%	10.2%	4.1%	14.6%	-1.7%	21.7%	1.6%	52.6%	-2.6%	13.5%	2.1%
21	3,853	84.1%	N/A	10.6%	0.5%	65.7%	3.1%	14.6%	-3.8%	7.9%	1.0%	15.4%	-4.8%	20.2%	0.5%	50.7%	-4.8%	12.8%	2.3%
22	5,448	81.9%	N/A	8.5%	0.7%	65.2%	-0.6%	13.0%	-3.1%	7.8%	0.8%	13.9%	-3.7%	22.0%	3.4%	50.2%	2.5%	14.5%	3.1%
23	3,212	87.4%	N/A	9.7%	0.7%	63.9%	1.2%	14.0%	-3.9%	9.4%	1.8%	14.7%	-4.9%	22.6%	2.6%	53.3%	1.4%	13.8%	2.5%
Min		79.0%		6.3%	-1.0%	59.6%	-2.6%	7.8%	-6.6%	5.0%	-1.2%	8.2%	-7.7%	19.0%	-1.2%	43.7%	-4.8%	11.8%	-1.8%
Max		87.4%		12.7%	1.8%	67.5%	3.1%	16.0%	0.2%	14.4%	7.1%	17.6%	-1.4%	28.3%	3.7%	62.4%	3.1%	18.5%	4.8%
Mean	4,384	84.2%		9.1%	0.5%	64.2%	0.5%	12.6%	-3.0%	8.9%	1.3%	13.0%	-3.9%	23.7%	2.3%	51.5%	-0.3%	14.9%	2.7%
Std. Dev.	1,725	2.2%		1.8%	0.8%	2.2%	1.4%	1.9%	1.6%	2.5%	2.0%	2.2%	1.7%	2.5%	1.2%	4.0%	2.4%	1.7%	1.4%
Coeff. of Var.	0.39	0.03		0.20	-0.8%	0.03	-10.7%	0.15	-4.2%	0.28	9.1%	0.17	9.8%	0.10	-17.8%	0.08	0.2%	0.12	-13.7%

Table 2b. VISN-level pharmacy measures -- Fiscal Year 2004 (continued)

		Percent prescribed any conventional		Percent prescribed any atypical		Percent prescribed clozapine		Percent prescribed olanzapine		Percent prescribed quetiapine		Percent prescribed risperidone		Percent prescribed ziprasidone		Percent prescribed aripiprazole	
VISN	N	Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from	
		FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003
1	4,534	23.5%	1.8%	81.4%	-2.5%	4.2%	-1.5%	26.9%	-3.8%	19.5%	-0.4%	29.9%	0.6%	4.2%	-0.1%	3.1%	2.1%
2	2,518	27.0%	0.1%	77.9%	-0.4%	3.0%	0.2%	25.0%	-1.8%	18.0%	0.0%	28.4%	-2.2%	4.1%	1.8%	4.4%	2.5%
3	5,050	27.8%	0.4%	78.8%	0.3%	1.7%	-0.4%	25.5%	-2.4%	15.4%	2.1%	33.7%	-1.3%	3.1%	0.2%	2.8%	2.1%
4	5,693	29.8%	0.0%	76.3%	0.1%	1.8%	0.0%	23.5%	-3.8%	18.8%	1.2%	27.2%	-1.4%	4.1%	0.8%	1.4%	1.1%
5	2,675	20.6%	2.0%	85.4%	-0.8%	1.3%	-0.1%	28.1%	-4.7%	17.1%	0.3%	31.0%	-2.3%	5.6%	0.2%	6.0%	4.2%
6	4,028	26.8%	0.7%	77.8%	0.4%	1.7%	0.0%	20.6%	-4.0%	17.3%	2.4%	32.3%	-1.4%	5.4%	0.6%	3.5%	3.2%
7	6,091	19.0%	-0.6%	85.0%	0.5%	2.1%	0.1%	23.7%	-4.8%	22.9%	2.5%	30.1%	0.0%	6.3%	0.7%	2.6%	2.0%
8	9,117	22.9%	1.1%	80.7%	-0.9%	1.1%	-0.1%	32.4%	-5.3%	17.9%	2.1%	26.2%	0.6%	3.3%	0.5%	2.5%	1.7%
9	3,382	26.2%	-0.6%	77.8%	0.0%	1.9%	0.0%	21.2%	-3.0%	18.3%	2.1%	30.5%	-1.2%	6.1%	0.5%	1.5%	0.9%
10	4,422	26.1%	2.3%	78.8%	-2.7%	2.6%	-2.5%	25.9%	-3.2%	20.7%	0.0%	25.0%	0.9%	5.0%	0.7%	1.7%	0.4%
11	4,666	25.7%	1.8%	80.3%	-1.4%	3.4%	-0.1%	25.8%	-5.2%	15.0%	1.6%	34.7%	0.6%	3.1%	0.8%	1.3%	1.0%
12	3,694	20.9%	0.9%	83.6%	-0.4%	3.4%	-0.2%	24.1%	-2.9%	17.1%	1.0%	35.5%	-0.4%	4.3%	0.7%	3.0%	1.4%
15	3,901	25.7%	1.8%	82.0%	-1.3%	1.9%	-0.2%	26.1%	-3.6%	20.3%	1.9%	31.3%	-0.9%	5.6%	1.4%	1.8%	0.8%
16	7,776	21.0%	2.3%	83.3%	-2.5%	1.6%	0.0%	21.6%	-8.2%	21.1%	2.8%	34.4%	0.1%	5.2%	0.5%	3.0%	1.9%
17	3,688	16.1%	-0.1%	87.7%	0.2%	3.3%	0.1%	28.3%	-6.0%	20.8%	2.2%	30.8%	0.1%	4.8%	0.6%	3.2%	1.7%
18	2,739	20.3%	0.4%	83.2%	-0.9%	1.7%	0.3%	25.8%	-3.0%	17.1%	1.0%	31.0%	-3.0%	5.9%	1.4%	4.0%	2.1%
19	2,049	21.5%	-0.3%	84.3%	0.9%	4.7%	-0.3%	29.8%	-4.9%	19.9%	4.4%	27.7%	-0.3%	3.5%	0.4%	3.5%	1.4%
20	3,528	20.0%	0.6%	83.7%	-0.5%	3.0%	-0.1%	25.4%	-2.7%	19.7%	0.5%	26.9%	-2.3%	6.3%	0.8%	5.9%	3.3%
21	3,853	18.5%	-1.1%	86.2%	0.5%	2.8%	0.0%	36.6%	-4.7%	19.8%	3.3%	26.0%	0.4%	4.0%	0.9%	2.1%	1.1%
22	5,448	20.1%	0.9%	83.8%	-0.6%	2.3%	0.1%	20.6%	-2.1%	23.0%	0.6%	33.5%	-2.4%	4.9%	1.1%	3.7%	2.3%
23	3,212	21.3%	0.6%	83.5%	-0.9%	4.6%	0.3%	30.7%	-3.6%	17.6%	0.5%	26.9%	-0.1%	5.0%	0.5%	3.2%	2.2%
Min		16.1%	-1.1%	76.3%	-2.7%	1.1%	-2.5%	20.6%	-8.2%	15.0%	-0.4%	25.0%	-3.0%	3.1%	-0.1%	1.3%	0.4%
Max		29.8%	2.3%	87.7%	0.9%	4.7%	0.3%	36.6%	-1.8%	23.0%	4.4%	35.5%	0.9%	6.3%	1.8%	6.0%	4.2%
Mean	4,384	22.9%	0.7%	82.0%	-0.6%	2.6%	-0.2%	26.1%	-4.0%	18.9%	1.5%	30.1%	-0.8%	4.8%	0.7%	3.1%	1.9%
Std. Dev.	1,725	3.6%	1.0%	3.2%	1.0%	1.1%	0.6%	4.0%	1.5%	2.2%	1.2%	3.1%	1.2%	1.0%	0.4%	1.3%	0.9%
Coeff. of Var.	0.39	0.16	-1.9%	0.04	-0.5%	0.41	-14.2%	0.15	1.2%	0.11	-15.5%	0.10	-9.1%	0.22	-15.8%	0.42	-21.0%

Table 3a. Station-level pharmacy measures -- Fiscal Year 2004

				Percent prescribed any antipsychotic	Percent with polypharmacy in past week	Percent dosed within PORT recommended range	Percent dosed higher than PORT recommended range	Percent dosed high on conventionals	Percent dosed high on atypicals	Percent dosed lower than PORT recommended range	Percent dosed low on conventionals	Percent dosed low on atypicals									
VISN	Station	Station name	N	Change from FY 2004 FY 2003	Change from FY 2004 FY 2003	Change from FY 2004 FY 2003	Change from FY 2004 FY 2003	Change from FY 2004 FY 2003	Change from FY 2004 FY 2003	Change from FY 2004 FY 2003	Change from FY 2004 FY 2003	Change from FY 2004 FY 2003									
1	402	TOGUS	498	89.4%	N/A	16.9%	-0.2%	60.9%	-0.6%	12.6%	-5.6%	4.8%	-2.7%	13.7%	-6.0%	27.0%	4.2%	58.7%	7.5%	14.5%	2.9%
1	405	WHITE RIVER JCT	165	87.3%	N/A	9.7%	-0.9%	64.6%	3.7%	13.2%	-0.1%	10.0%	3.3%	13.2%	-1.4%	22.9%	-3.6%	67.5%	-3.6%	5.3%	-2.4%
1	518	BEDFORD	488	88.9%	N/A	20.3%	3.3%	56.2%	2.0%	20.5%	-3.5%	9.2%	0.3%	22.7%	-4.1%	24.2%	1.0%	56.3%	-0.8%	11.8%	-0.9%
1	523	BOSTON	1,405	76.1%	N/A	12.3%	-1.6%	57.8%	-1.9%	12.1%	-3.5%	6.4%	1.3%	13.1%	-4.2%	30.7%	5.3%	59.1%	4.6%	22.4%	5.4%
1	608	MANCHESTER	156	85.9%	N/A	11.2%	-5.5%	54.5%	7.4%	9.0%	-9.2%	4.7%	-0.6%	10.2%	-10.7%	36.6%	1.8%	65.1%	2.0%	22.4%	-0.3%
1	631	NORTHAMPTON	364	86.3%	N/A	10.5%	1.5%	64.3%	7.8%	11.8%	-10.5%	4.4%	4.4%	12.7%	-13.2%	23.9%	2.7%	57.8%	4.4%	17.8%	3.0%
1	650	PROVIDENCE	491	85.7%	N/A	7.6%	-3.4%	66.3%	6.8%	16.4%	-5.9%	15.4%	6.8%	16.5%	-7.0%	17.3%	-1.2%	46.2%	-7.3%	12.1%	-1.1%
1	689	WEST HAVEN	967	76.9%	N/A	6.6%	-2.1%	62.4%	-2.8%	10.2%	-4.6%	8.0%	2.3%	10.8%	-5.7%	27.4%	6.7%	55.2%	4.4%	16.0%	4.8%
2	528	UPSTATE N.Y. HCS	2,518	83.7%	N/A	10.3%	0.9%	59.6%	2.4%	15.2%	-1.4%	6.2%	-1.0%	17.6%	-1.4%	25.7%	-1.2%	57.4%	0.8%	13.7%	-1.8%
3	526	BRONX	580	83.4%	N/A	5.6%	0.5%	67.6%	0.9%	7.4%	-4.8%	6.3%	0.7%	7.5%	-6.3%	25.0%	3.8%	55.9%	3.9%	13.7%	1.9%
3	561	EAST ORANGE	1,343	86.2%	N/A	10.5%	0.9%	64.9%	1.7%	15.9%	-1.6%	11.5%	-0.7%	16.5%	-2.0%	19.3%	-0.5%	44.1%	-4.0%	9.4%	-0.4%
3	620	MONTROSE	646	90.6%	N/A	16.1%	1.8%	59.8%	1.6%	17.3%	-3.4%	17.0%	-0.8%	16.5%	-5.0%	23.4%	1.4%	39.2%	-1.2%	15.6%	3.7%
3	630	N.Y. HARBOR HCS	1,758	78.2%	N/A	10.9%	2.7%	63.3%	-2.7%	11.5%	-0.1%	6.3%	2.7%	12.4%	-1.3%	25.5%	3.0%	54.5%	4.1%	14.2%	2.2%
3	632	NORTHPORT	723	79.3%	N/A	10.8%	1.0%	59.7%	-1.8%	8.9%	-2.2%	4.5%	-0.6%	9.9%	-2.5%	31.8%	3.7%	53.1%	0.5%	19.6%	4.9%
4	460	WILMINGTON	312	71.5%	N/A	5.8%	-1.2%	65.9%	5.4%	9.0%	-10.8%	5.5%	3.9%	9.7%	-15.1%	25.1%	4.1%	49.1%	-4.9%	16.5%	7.5%
4	503	JAMES E VAN ZAND	207	83.6%	N/A	5.2%	-3.4%	54.9%	-4.0%	8.7%	-0.5%	6.8%	1.5%	9.2%	-1.3%	36.4%	3.9%	57.6%	-3.8%	25.0%	9.3%
4	529	BUTLER	142	86.6%	N/A	8.1%	3.1%	61.0%	-0.6%	8.9%	0.9%	2.7%	2.7%	11.2%	0.8%	30.1%	-0.2%	56.8%	-7.2%	19.1%	0.9%
4	540	CLARKSBURG	250	86.0%	N/A	11.2%	1.6%	61.9%	-3.4%	8.8%	-2.1%	3.8%	-1.1%	10.3%	-2.1%	29.3%	5.0%	67.9%	2.1%	17.1%	3.7%
4	542	COATESVILLE	499	89.0%	N/A	9.9%	-1.7%	65.5%	-2.4%	11.7%	-4.9%	21.6%	8.3%	9.1%	-7.5%	23.4%	7.6%	47.7%	4.4%	16.6%	7.6%
4	562	ERIE	225	79.6%	N/A	8.9%	-1.9%	53.1%	-4.0%	7.8%	-2.0%	2.1%	2.1%	9.0%	-3.1%	40.2%	6.5%	76.6%	2.1%	25.7%	8.2%
4	595	LEBANON	641	87.4%	N/A	12.3%	2.1%	64.1%	1.0%	10.4%	-1.6%	7.1%	0.4%	10.5%	-2.4%	25.9%	0.5%	52.7%	1.9%	12.6%	-0.1%
4	642	PHILADELPHIA	1,537	82.6%	N/A	7.2%	0.3%	63.9%	2.8%	9.8%	-3.7%	8.7%	0.7%	9.7%	-5.7%	26.3%	0.6%	51.4%	0.5%	13.7%	0.1%
4	646	PITTSBURGH-UNIV	1,272	89.4%	N/A	12.5%	1.0%	61.3%	3.4%	11.6%	-3.5%	6.1%	1.2%	12.5%	-5.5%	27.9%	-0.2%	50.0%	-3.7%	17.1%	2.5%
4	693	WILKES BARRE	608	83.1%	N/A	8.1%	1.7%	51.7%	-6.7%	13.3%	0.1%	13.7%	2.3%	12.1%	-1.6%	35.1%	5.9%	57.1%	1.5%	24.0%	7.8%
5	512	BALTIMORE	1,210	85.5%	N/A	13.0%	1.7%	64.9%	2.4%	13.3%	-5.7%	13.2%	0.3%	11.9%	-7.4%	22.1%	3.2%	42.0%	2.3%	14.2%	2.4%
5	613	MARTINSBURG	355	86.8%	N/A	9.1%	0.6%	69.8%	7.2%	11.4%	-8.1%	1.7%	-2.9%	12.9%	-8.9%	19.8%	0.7%	55.0%	-2.6%	11.0%	2.1%
5	688	WASHINGTON	1,110	80.1%	N/A	9.7%	0.9%	67.2%	2.0%	10.9%	-7.3%	9.3%	-3.8%	10.8%	-7.6%	21.9%	5.3%	55.1%	9.5%	17.4%	4.7%
6	517	BECKLEY	158	81.6%	N/A	8.5%	-0.8%	65.9%	2.6%	6.2%	-0.8%	0.0%	-2.3%	8.2%	-0.5%	27.9%	-1.8%	60.5%	2.4%	14.4%	0.1%
6	558	DURHAM	551	82.4%	N/A	5.7%	-1.1%	60.4%	0.7%	17.8%	-0.4%	18.6%	2.9%	16.7%	-2.2%	22.0%	-0.5%	43.4%	-10.1%	11.4%	2.7%
6	565	FAYETTEVILLE NC	558	84.6%	N/A	5.5%	1.7%	64.6%	-1.8%	9.3%	-2.0%	3.9%	-2.5%	10.1%	-2.1%	26.1%	3.8%	66.2%	6.0%	18.2%	3.8%
6	590	HAMPTON	631	85.7%	N/A	5.5%	2.3%	67.7%	-0.8%	12.2%	-1.3%	14.1%	3.2%	11.1%	-2.9%	20.3%	2.2%	45.6%	-2.7%	10.9%	3.6%
6	637	ASHEVILLE-OTEEEN	277	83.0%	N/A	5.2%	2.2%	61.7%	1.2%	8.3%	-5.2%	4.6%	-1.9%	9.5%	-6.5%	30.0%	3.5%	49.2%	3.3%	21.9%	4.5%
6	652	RICHMOND	510	84.1%	N/A	10.5%	1.9%	63.6%	-0.4%	9.6%	-2.4%	10.0%	3.5%	8.5%	-4.6%	27.5%	3.3%	51.5%	1.1%	16.7%	1.8%
6	658	SALEM	600	89.7%	N/A	11.7%	2.8%	63.9%	-1.7%	13.9%	-0.7%	11.3%	1.8%	13.6%	-2.2%	22.7%	2.5%	41.0%	-1.4%	10.8%	2.1%
6	659	SALISBURY	743	88.2%	N/A	9.8%	3.3%	60.6%	-0.5%	14.4%	-1.1%	8.7%	4.5%	15.3%	-2.4%	25.0%	1.0%	56.3%	-3.2%	16.7%	2.8%
7	508	ATLANTA	1,233	86.2%	N/A	10.0%	2.3%	64.1%	-4.0%	13.8%	0.7%	6.7%	2.0%	14.8%	0.1%	22.6%	3.3%	46.7%	0.8%	15.8%	3.9%
7	509	AUGUSTA	701	84.6%	N/A	4.7%	0.7%	64.3%	-0.2%	15.3%	-2.4%	5.9%	-0.7%	17.1%	-2.6%	20.4%	2.4%	50.4%	0.8%	12.6%	1.8%
7	521	BIRMINGHAM	834	87.3%	N/A	8.2%	0.3%	67.0%	0.6%	11.4%	-3.8%	8.3%	-0.8%	11.5%	-4.6%	22.3%	3.5%	54.2%	-1.6%	15.6%	5.4%
7	534	CHARLESTON	663	84.5%	N/A	9.1%	-0.3%	67.7%	-2.1%	8.6%	-1.6%	5.8%	0.4%	8.7%	-2.1%	24.1%	3.1%	52.5%	-2.1%	15.7%	6.3%
7	544	COLUMBIA SC	821	85.5%	N/A	10.3%	-2.3%	62.0%	0.5%	12.5%	-3.4%	15.2%	4.7%	11.4%	-5.1%	25.9%	2.9%	50.3%	-5.9%	18.6%	5.9%
7	557	DUBLIN	418	80.9%	N/A	2.7%	0.9%	75.4%	-0.8%	5.0%	-3.6%	2.8%	-5.1%	5.2%	-3.4%	19.5%	4.4%	58.3%	3.1%	15.0%	3.9%
7	619	MONTGOMERY	1,041	84.9%	N/A	3.1%	-1.2%	66.4%	-2.8%	7.8%	-1.8%	2.6%	-5.1%	8.4%	-1.2%	26.1%	4.8%	58.3%	5.3%	20.9%	4.5%
7	679	TUSCALOOSA	380	90.8%	N/A	7.0%	1.2%	64.3%	0.8%	11.9%	-4.0%	13.5%	1.3%	9.9%	-7.3%	23.8%	2.7%	42.1%	-1.1%	12.0%	2.9%
8	516	BAY PINES	915	85.0%	N/A	6.3%	0.2%	64.7%	3.5%	15.6%	-3.9%	9.1%	1.9%	16.8%	-5.0%	19.8%	-0.1%	50.6%	-5.1%	11.4%	1.0%
8	546	MIAMI	1,317	83.3%	N/A	10.3%	3.4%	53.4%	-5.6%	25.9%	6.2%	50.9%	33.0%	14.6%	-4.7%	21.3%	-0.6%	27.2%	-17.9%	17.1%	3.4%
8	548	W PALM BEACH	463	84.7%	N/A	10.5%	0.6%	60.7%	-0.4%	20.9%	-5.4%	9.0%	5.5%	22.3%	-6.4%	18.6%	5.6%	46.3%	4.9%	12.6%	4.6%
8	573	N FL/S GA HCS	1,425	85.0%	N/A	8.1%	0.9%	68.2%	-2.7%	12.1%	1.0%	7.4%	0.6%	12.5%	0.9%	20.3%	1.8%	53.0%	0.8%	12.5%	2.9%
8	672	SAN JUAN	3,255	80.0%	N/A	3.4%	0.3%	63.5%	-3.0%	3.0%	-0.4%	1.3%	-1.3%	3.3%	-0.2%	33.5%	3.4%	72.8%	7.0%	25.3%	3.6%
8	673	TAMPA	1,742	86.1%	N/A	6.9%	0.5%	57.7%	-3.3%	13.7%	-0.5%	6.2%	0.1%	16.6%	0.0%	28.7%	3.8%	51.6%	1.3%	17.3%	3.6%
9	581	HUNTINGTON	310	87.7%	N/A	5.1%	-0.6%	55.1%	0.2%	9.2%	-7.2%	4.7%	-1.4%	10.1%	-9.7%	35.7%	6.3%	65.6%	-1.0%	26.3%	10.3%
9	596	LEXINGTON-LEESTO	324	84.3%	N/A	8.1%	-0.7%	65.9%	4.6%	9.5%	-7.9%	0.0%	-4.1%	10.9%	-8.2%	24.9%	3.7%	57.4%	-7.9%	17.6%	5.6%
9	603	LOUISVILLE	457	88.0%	N/A	8.0%	0.2%	64.2%	0.0%	7.0%	-2.7%	4.9%	0.9%	7.3%	-3.6%	29.1%	2.5%	69.9%	2.6%	14.9%	1.3%
9	614	MEMPHIS	682	78.9%	N/A	3.0%	-0.2%	71.9%	2.4%	10.8%	-2.9%	5.9%	0.3%	12.3%	-4.7%	17.5%	0.7%	44.1%	0.3%	7.1%	3.0%
9	621	MOUNTAIN HOME	318	77.4%	N/A	3.7%	-1.3%	58.1%	-5.0%	7.7%	-1.7%	10.8%	3.5%	7.2%	-3.3%	34.1%	6.4%	54.1%	-0.4%	24.3%	5.9%
9	626	VA MID TENN HCS	1,291	85.1%	N/A	9.0%	-0.4%	62.9%	-0.6%	11.											

				Percent prescribed any antipsychotic	Percent with polypharmacy in past week	Percent dosed within PORT recommended range	Percent dosed higher than PORT recommended range	Percent dosed high on conventionals	Percent dosed high on atypicals	Percent dosed lower than PORT recommended range	Percent dosed low on conventionals	Percent dosed low on atypicals	
Change from					Change from	Change from	Change from	Change from	Change from	Change from	Change from	Change from	
VISN	Station	Station name	N	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003
11	550	ILLIANA HCS DANV	496	88.3%	N/A	5.7%	-0.3%	62.1%	1.9%	20.1%	-0.9%	10.6%	1.9%
11	553	DETROIT VAMC	1,109	88.0%	N/A	6.7%	-0.4%	68.8%	0.7%	12.4%	-3.5%	21.1%	3.2%
11	583	INDIANAPOLIS-10T	543	84.7%	N/A	12.6%	5.5%	64.3%	-2.3%	17.4%	0.6%	15.9%	3.2%
11	610	NORTHERN INDIANA	623	86.2%	N/A	10.4%	1.6%	59.6%	-1.6%	16.6%	-2.1%	13.1%	-1.3%
11	655	SAGINAW	346	83.5%	N/A	9.7%	2.9%	64.0%	-2.2%	12.5%	-1.8%	5.4%	2.3%
12	537	VA CHICAGO HCS	1,271	81.1%	N/A	4.3%	0.0%	65.7%	-1.5%	10.2%	0.1%	10.9%	5.6%
12	556	NORTH CHICAGO	332	78.9%	N/A	5.7%	0.3%	67.6%	-0.2%	10.7%	-1.4%	9.9%	-1.4%
12	578	HINES	620	83.1%	N/A	11.3%	3.3%	68.5%	-3.4%	8.5%	-0.7%	1.3%	-1.1%
12	585	IRON MOUNTAIN	171	88.3%	N/A	22.5%	-4.5%	59.6%	3.5%	14.6%	-4.3%	8.5%	0.0%
12	607	MADISON	304	86.2%	N/A	7.6%	-0.1%	72.5%	7.0%	12.6%	-6.0%	2.6%	0.3%
12	676	TOMAH	293	89.1%	N/A	11.5%	3.2%	67.8%	3.9%	15.3%	-3.8%	5.0%	2.1%
12	695	MILWAUKEE	703	84.1%	N/A	12.9%	2.8%	68.4%	0.4%	9.3%	-0.5%	7.6%	2.2%
15	589	VAMC HEARTLAND-V	1,976	84.7%	N/A	9.7%	0.5%	64.9%	2.1%	15.1%	-5.4%	12.0%	1.4%
15	657	VA HEARTLAND-E V	1,925	89.2%	N/A	15.7%	2.6%	63.3%	0.9%	11.9%	-2.4%	8.1%	0.7%
16	502	ALEXANDRIA	610	88.4%	N/A	12.8%	0.3%	67.5%	2.9%	13.2%	-8.1%	11.0%	3.6%
16	520	GULF COAST HCS	1,383	85.5%	N/A	7.8%	-6.7%	64.0%	2.3%	15.6%	-4.3%	10.0%	-1.5%
16	564	FAYETTEVILLE AR	391	81.1%	N/A	11.0%	1.2%	68.5%	0.2%	12.6%	-4.3%	9.2%	-2.3%
16	580	HOUSTON	1,423	88.5%	N/A	10.6%	2.8%	67.5%	0.4%	14.5%	-3.5%	11.4%	-1.0%
16	586	JACKSON	627	84.5%	N/A	5.8%	-2.2%	68.9%	1.1%	9.8%	-3.7%	5.3%	2.1%
16	598	LITTLE ROCK	735	88.6%	N/A	6.8%	0.3%	65.6%	-1.9%	12.9%	-2.5%	4.7%	-2.3%
16	623	MUSKOGEE	379	85.0%	N/A	10.9%	3.2%	65.2%	-1.0%	8.4%	-1.7%	3.6%	1.4%
16	629	NEW ORLEANS	996	86.9%	N/A	10.4%	3.7%	62.7%	-5.5%	15.8%	-2.0%	8.1%	-0.6%
16	635	OKLAHOMA CITY	664	82.7%	N/A	6.9%	1.2%	69.9%	-1.8%	6.0%	-4.6%	3.0%	-3.1%
16	667	SHREVEPORT	568	82.0%	N/A	6.2%	0.9%	62.2%	3.4%	6.2%	-3.4%	2.7%	0.0%
17	549	DALLAS	1,426	81.5%	N/A	7.7%	-1.4%	68.2%	2.0%	10.2%	-4.9%	2.5%	-0.5%
17	671	SAN ANTONIO	1,015	86.6%	N/A	9.8%	-0.2%	65.5%	0.2%	17.4%	-1.2%	11.6%	3.3%
17	674	VA CENTRAL TEXAS	1,247	82.1%	N/A	6.2%	-1.1%	68.5%	4.0%	14.9%	-7.6%	11.7%	-0.5%
18	501	NEW MEXICO HCS	543	75.9%	N/A	3.6%	-1.0%	68.9%	1.0%	7.8%	-4.5%	3.6%	2.0%
18	504	AMARILLO HCS	181	85.1%	N/A	4.5%	-1.5%	47.4%	-1.2%	8.8%	0.4%	1.4%	-3.7%
18	519	WEST TEXAS HCS	192	83.3%	N/A	5.6%	1.0%	62.5%	-6.8%	9.4%	-5.7%	0.0%	0.0%
18	644	PHOENIX	858	79.7%	N/A	6.7%	-0.8%	69.3%	1.4%	6.9%	-1.6%	7.6%	0.7%
18	649	NORTHERN ARIZONA	230	72.2%	N/A	7.8%	3.6%	60.8%	2.3%	10.8%	2.9%	2.9%	0.1%
18	678	SOUTHERN ARIZONA	458	83.4%	N/A	8.9%	1.1%	69.9%	6.8%	7.1%	-8.8%	10.3%	2.1%
18	756	EL PASO HCS	277	74.0%	N/A	6.3%	1.3%	69.8%	-2.3%	9.8%	2.0%	3.4%	3.4%
19	436	FORT HARRISON	236	86.0%	N/A	12.8%	7.3%	62.6%	-2.1%	12.3%	-4.7%	2.8%	-12.4%
19	442	CHEYENNE	133	90.2%	N/A	8.3%	-8.0%	66.7%	3.9%	10.0%	-4.5%	11.1%	7.5%
19	554	DENVER	889	85.0%	N/A	9.8%	0.7%	62.4%	-0.1%	12.7%	-2.2%	6.2%	0.5%
19	575	GRAND JUNCTION	161	87.0%	N/A	17.9%	3.0%	55.0%	2.5%	13.6%	-1.3%	6.5%	1.4%
19	660	SALT LAKE CITY H	477	88.5%	N/A	8.3%	-1.2%	65.4%	-2.2%	12.6%	-0.6%	0.0%	-1.7%
19	666	SHERIDAN	153	92.8%	N/A	22.5%	6.4%	64.8%	-0.3%	10.4%	-10.7%	9.5%	-0.5%
20	463	ALASKA HCS & RO	89	87.6%	N/A	5.1%	2.2%	74.4%	4.8%	17.9%	2.0%	16.7%	5.6%
20	531	BOISE	286	87.1%	N/A	8.4%	-0.8%	59.4%	-2.4%	16.1%	2.8%	12.9%	9.1%
20	648	PORTLAND	882	83.8%	N/A	5.0%	0.3%	61.4%	-2.3%	13.9%	-1.9%	11.5%	2.6%
20	653	VA ROSEBURG HCS	353	88.1%	N/A	10.0%	2.6%	66.6%	0.6%	12.9%	-2.5%	9.5%	4.3%
20	663	PUGET SOUND HCS	1,266	86.7%	N/A	7.1%	-0.3%	65.9%	1.1%	16.0%	-0.5%	11.0%	5.4%
20	668	SPOKANE	251	85.3%	N/A	8.4%	0.0%	72.4%	-2.8%	7.9%	-1.5%	61.9%	-6.3%
20	687	WALLA WALLA	154	81.8%	N/A	7.1%	-2.2%	61.9%	3.3%	12.7%	-0.6%	5.7%	3.1%
20	692	WHITE CITY	247	82.2%	N/A	15.3%	6.2%	61.1%	-7.1%	10.8%	-0.5%	2.9%	0.1%
21	358	MANILA	16	56.3%	N/A	0.0%	-35.3%	55.6%	14.5%	11.1%	3.2%	25.0%	23.8%
21	459	HONOLULU	518	87.3%	N/A	11.5%	2.4%	62.2%	-2.6%	13.9%	0.5%	6.8%	1.6%
21	570	CENTRAL CALIFORN	352	84.9%	N/A	4.3%	-1.3%	77.3%	9.3%	9.0%	-10.0%	0.0%	-1.8%
21	612	NCHC MARTINEZ	1,066	83.7%	N/A	9.0%	0.4%	63.3%	1.0%	14.9%	-2.1%	10.2%	0.2%
21	640	PALO ALTO-PALO A	1,034	88.1%	N/A	12.5%	2.0%	67.3%	6.6%	15.7%	-7.9%	10.5%	-2.3%
21	654	SIERRA NEVADA HC	259	80.3%	N/A	11.5%	5.5%	72.6%	-0.5%	10.6%	-1.0%	6.7%	6.7%
21	662	SAN FRANCISCO	608	77.1%	N/A	12.6%	2.7%	60.6%	-3.6%	14.3%	-3.0%	4.0%	0.0%
22	593	LAS VEGAS	505	81.6%	N/A	8.3%	0.5%	64.8%	-1.5%	14.1%	-1.9%	6.8%	3.1%
22	600	VA LONG BEACH HC	768	86.2%	N/A	13.0%	2.7%	61.2%	-3.5%	18.3%	-0.4%	7.0%	-1.3%
22	605	LOMA LINDA	761	83.4%	N/A	9.6%	0.5%	64.7%	-0.2%	12.1%	-3.7%	11.1%	1.7%
22	664	VA SAN DIEGO HCS	998	85.8%	N/A	8.4%	-1.1%	60.7%	0.4%	13.9%	-3.2%	11.5%	2.8%
22	691	GREATER LA HCS	2,416	78.5%	N/A	6.7%	0.8%	68.8%	0.3%	10.9%	-4.0%	4.7%	-0.4%
23	437	FARGO	207	86.5%	N/A	6.1%	-2.8%	67.6%	5.0%	14.5%	-3.9%	0.0%	0.0%
23	438	SIOUX FALLS	251	88.4%	N/A	13.5%	0.1%	55.9%	-7.7%	15.3%	-1.7%	9.8%	1.8%
23	568	FORT MEADE	222	88.7%	N/A	15.7%	-0.2%	52.8%	-5.0%	17.8%	2.3%	10.2%	2.6%
23	618	MINNEAPOLIS	890	84.3%	N/A	7.2%	0.6%	70.5%	5.2%	9.7%	-8.1%	8.1%	0.5%

				Percent prescribed any antipsychotic	Percent with polypharmacy in past week	Percent dosed within PORT recommended range	Percent dosed higher than PORT recommended range	Percent dosed high on conventionals	Percent dosed high on atypicals	Percent dosed lower than PORT recommended range	Percent dosed low on conventionals	Percent dosed low on atypicals	
				Change from FY 2004 FY 2003	Change from FY 2004 FY 2003	Change from FY 2004 FY 2003	Change from FY 2004 FY 2003	Change from FY 2004 FY 2003	Change from FY 2004 FY 2003	Change from FY 2004 FY 2003	Change from FY 2004 FY 2003	Change from FY 2004 FY 2003	
VISN	Station	Station name	N	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003
23	636	VA NEB-WESTERN I	1,339	88.3%	N/A	10.7%	2.0%	62.2%	0.3%	14.7%	-3.3%	10.2%	1.9%
23	656	ST CLOUD	303	91.7%	N/A	7.2%	-0.9%	64.7%	3.4%	18.0%	-1.7%	11.1%	3.9%
				15.8%	-4.1%	23.4%	2.8%	49.5%	1.8%	18.9%	-2.9%	18.0%	-2.0%
				55.6%	-5.3%			8.8%	1.0%				
Min				56.3%		0.0%	-35.3%	47.4%	-10.6%	3.0%	-10.8%	0.0%	-15.1%
Max				92.8%		22.5%	7.3%	77.3%	14.5%	25.9%	6.2%	50.9%	33.0%
Mean			719	84.3%		9.0%	0.3%	63.8%	0.3%	12.3%	-2.8%	8.4%	1.5%
Std. Dev.			549	4.7%		3.8%	3.9%	5.0%	3.7%	3.7%	3.0%	6.3%	4.9%
Coeff. of Var.			0.76	0.06		0.42	-14.4%	0.08	-2.3%	0.30	6.7%	0.75	27.4%
										0.31	11.1%	0.22	-19.4%
										0.20	22.2%	0.38	21.2%

Table 3b. Station-level pharmacy measures -- Fiscal Year 2004 (continued)

VISN	Station	Station name	N	Percent prescribed any conventional		Percent prescribed any atypical		Percent prescribed clozapine		Percent prescribed olanzapine		Percent prescribed quetiapine		Percent prescribed risperidone		Percent prescribed ziprasidone		Percent prescribed aripiprazole	
				Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from	
				FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003
1	402	TOGUS	498	28.3%	1.5%	82.2%	0.2%	6.1%	-0.1%	30.1%	-4.2%	18.4%	-1.0%	24.9%	1.1%	5.2%	0.3%	2.2%	1.4%
1	405	WHITE RIVER JCT	165	27.8%	-2.0%	79.2%	1.7%	4.2%	-0.5%	26.4%	5.9%	12.5%	-2.7%	26.4%	-4.7%	8.3%	-0.9%	4.2%	3.5%
1	518	BEDFORD	488	27.4%	3.6%	80.2%	-1.7%	7.8%	-0.9%	20.5%	-4.4%	24.0%	-1.8%	27.9%	-1.5%	4.6%	1.4%	9.4%	7.5%
1	523	BOSTON	1,405	20.6%	0.5%	83.5%	-2.1%	4.2%	0.0%	27.2%	-3.5%	25.4%	-0.5%	27.6%	-1.1%	3.4%	0.0%	2.8%	1.9%
1	608	MANCHESTER	156	32.1%	4.6%	73.1%	-6.6%	3.0%	0.1%	22.4%	-6.6%	23.9%	0.7%	23.9%	-6.6%	1.5%	0.0%	7.5%	3.8%
1	631	NORTHAMPTON	364	14.3%	-2.6%	87.9%	1.7%	5.7%	-1.0%	29.6%	-5.1%	19.1%	3.3%	38.9%	6.9%	2.9%	-0.2%	0.3%	0.3%
1	650	PROVIDENCE	491	15.4%	0.9%	86.5%	-2.8%	5.2%	0.2%	30.4%	-3.1%	13.1%	-3.9%	34.2%	-0.8%	4.8%	-0.2%	4.3%	3.3%
1	689	WEST HAVEN	967	28.5%	5.3%	75.0%	-7.0%	0.0%	-6.4%	26.1%	-5.1%	13.6%	1.6%	32.8%	4.1%	4.7%	-1.4%	0.0%	-1.0%
2	528	UPSTATE N.Y. HCS	2,518	27.0%	0.1%	77.9%	-0.4%	3.0%	0.2%	25.0%	-1.8%	18.0%	0.0%	28.4%	-2.2%	4.1%	1.8%	4.4%	2.5%
3	526	BRONX	580	26.2%	1.9%	76.9%	-2.3%	1.2%	-0.9%	24.0%	-4.7%	13.6%	2.3%	32.0%	-2.5%	3.9%	0.6%	3.9%	2.8%
3	561	EAST ORANGE	1,343	27.1%	2.0%	79.2%	-1.2%	1.6%	-0.7%	20.4%	-2.3%	14.6%	2.2%	41.7%	-2.0%	3.2%	0.1%	1.9%	1.7%
3	620	MONTROSE	646	30.1%	-1.8%	79.8%	1.1%	3.9%	0.0%	25.8%	-1.7%	16.6%	-1.7%	30.4%	-0.6%	1.9%	1.0%	2.4%	1.5%
3	630	N.Y. HARBOR HCS	1,758	26.6%	0.1%	79.3%	1.8%	0.9%	0.1%	27.9%	-1.7%	15.9%	2.3%	31.4%	-1.0%	4.1%	-0.2%	4.1%	2.7%
3	632	NORTHPORT	723	31.2%	-0.7%	77.3%	1.0%	2.1%	-0.7%	31.2%	-3.3%	16.2%	5.6%	27.7%	-0.8%	1.0%	-0.1%	1.2%	1.2%
4	460	WILMINGTON	312	24.7%	-1.3%	78.9%	0.7%	0.0%	0.0%	32.7%	-1.0%	15.2%	2.1%	23.8%	-3.8%	6.3%	1.3%	0.4%	-0.8%
4	503	JAMES E VAN ZAND	207	34.1%	-0.9%	69.4%	-1.2%	1.2%	0.5%	23.1%	-5.1%	15.6%	-0.3%	21.4%	-3.8%	2.3%	-0.1%	2.9%	1.0%
4	529	BUTLER	142	30.1%	4.8%	72.4%	-5.4%	0.8%	-0.2%	28.5%	-8.9%	21.1%	7.0%	17.9%	-5.3%	5.7%	2.7%	0.8%	-0.2%
4	540	CLARKSBURG	250	24.7%	5.1%	81.4%	-3.4%	2.8%	0.4%	22.8%	-7.7%	31.6%	3.1%	21.4%	-3.4%	5.6%	1.3%	0.0%	0.0%
4	542	COATESVILLE	499	19.8%	1.1%	86.7%	-1.0%	2.0%	0.2%	23.4%	-6.3%	20.5%	1.2%	29.7%	-4.2%	5.4%	-0.8%	2.9%	1.9%
4	562	ERIE	225	26.3%	-1.5%	80.4%	-0.5%	0.6%	-1.1%	19.0%	-4.9%	15.1%	-3.9%	42.5%	7.7%	2.2%	-1.0%	0.6%	0.0%
4	595	LEBANON	641	32.5%	1.3%	76.8%	0.1%	0.9%	-0.5%	27.3%	-2.1%	16.6%	3.7%	31.1%	-0.3%	2.5%	-0.9%	0.4%	0.4%
4	642	PHILADELPHIA	1,537	32.6%	0.3%	71.3%	-0.6%	0.0%	-0.1%	25.3%	-2.3%	16.9%	-0.6%	26.2%	-0.5%	4.5%	2.1%	0.6%	0.6%
4	646	PITTSBURGH-UNIV	1,272	30.3%	-2.0%	78.3%	2.3%	4.0%	0.4%	21.0%	-2.5%	23.0%	2.3%	24.8%	-2.7%	3.9%	0.2%	2.4%	2.0%
4	693	WILKES BARRE	608	31.9%	-1.5%	73.5%	1.9%	3.2%	0.4%	17.2%	-8.4%	13.5%	0.5%	31.3%	1.7%	4.0%	2.2%	2.4%	2.2%
5	512	BALTIMORE	1,210	27.2%	2.9%	81.9%	-0.9%	1.5%	-0.2%	30.3%	-4.9%	14.9%	1.6%	31.1%	-0.7%	3.9%	-0.8%	2.1%	1.6%
5	613	MARTINSBURG	355	19.5%	-0.6%	85.4%	0.6%	1.0%	-0.5%	26.6%	-8.9%	15.9%	-2.3%	23.4%	0.0%	14.3%	4.9%	8.4%	8.1%
5	688	WASHINGTON	1,110	13.3%	1.5%	89.4%	-0.8%	1.4%	0.1%	26.1%	-3.2%	20.0%	0.0%	33.5%	-4.7%	4.5%	-0.4%	9.6%	6.0%
6	517	BECKLEY	158	29.5%	-4.1%	75.2%	4.1%	0.8%	-0.8%	18.6%	-0.1%	15.5%	3.8%	38.8%	-1.9%	0.8%	-0.8%	3.9%	3.9%
6	558	DURHAM	551	31.9%	1.9%	71.4%	-2.7%	1.5%	0.0%	20.0%	-2.7%	11.9%	2.7%	28.6%	-7.4%	5.3%	-1.6%	6.2%	6.2%
6	565	FAYETTEVILLE NC	558	16.3%	-0.4%	86.0%	1.6%	0.4%	0.0%	15.9%	-5.1%	16.5%	5.4%	49.2%	-4.2%	2.8%	1.5%	3.4%	3.4%
6	590	HAMPTON	631	27.5%	1.3%	76.3%	0.4%	1.5%	0.1%	26.1%	-3.5%	14.4%	2.3%	27.0%	-1.0%	5.9%	0.2%	2.6%	2.4%
6	637	ASHEVILLE-OTEEEN	277	28.3%	-2.2%	73.5%	1.5%	0.0%	0.0%	15.2%	-3.8%	26.5%	2.5%	25.7%	1.7%	7.0%	1.5%	1.7%	1.7%
6	652	RICHMOND	510	30.3%	4.6%	76.7%	-2.0%	0.9%	0.2%	20.3%	-7.8%	20.3%	1.3%	31.0%	-0.7%	3.7%	1.3%	4.0%	2.8%
6	658	SALEM	600	36.2%	3.0%	72.3%	-0.6%	4.6%	-0.2%	21.9%	-2.9%	12.8%	1.0%	29.2%	-0.5%	4.1%	-0.2%	2.0%	1.9%
6	659	SALISBURY	743	19.2%	-2.5%	84.9%	2.8%	1.8%	0.0%	21.1%	-3.5%	22.6%	1.1%	31.6%	2.4%	9.5%	2.2%	3.7%	3.7%
7	508	ATLANTA	1,233	19.8%	-0.5%	86.0%	0.9%	2.0%	0.2%	21.9%	-7.3%	22.5%	3.7%	32.3%	-2.0%	6.5%	3.9%	4.4%	3.7%
7	509	AUGUSTA	701	20.1%	2.2%	83.0%	-1.7%	7.6%	1.5%	31.7%	-4.3%	15.7%	1.9%	24.8%	1.5%	4.6%	-2.2%	0.3%	0.2%
7	521	BIRMINGHAM	834	16.5%	-2.7%	87.4%	2.0%	0.4%	-0.3%	24.2%	-4.2%	27.1%	2.0%	31.2%	-0.3%	4.7%	2.8%	4.3%	2.9%
7	534	CHARLESTON	663	21.4%	-3.0%	83.9%	2.4%	3.9%	0.5%	21.1%	-3.6%	13.8%	1.2%	34.8%	4.7%	11.6%	-1.4%	2.3%	1.0%
7	544	COLUMBIA SC	821	20.7%	-2.5%	83.5%	1.2%	0.4%	0.1%	26.1%	-4.2%	28.6%	1.4%	23.1%	-1.0%	7.1%	-0.3%	3.6%	3.6%
7	557	DUBLIN	418	10.7%	1.1%	90.8%	-0.6%	0.0%	-0.3%	21.0%	-3.2%	24.6%	2.1%	26.6%	-1.9%	16.6%	0.4%	2.1%	1.8%
7	619	MONTGOMERY	1,041	13.0%	0.2%	88.8%	-0.6%	0.0%	-0.2%	24.2%	-4.7%	26.8%	1.9%	34.5%	-0.1%	2.7%	0.0%	0.9%	0.8%
7	679	TUSCALOOSA	380	36.5%	2.0%	70.1%	-0.6%	4.9%	0.2%	15.9%	-3.9%	18.8%	4.2%	29.0%	0.2%	1.4%	-0.3%	0.3%	-1.2%
8	516	BAY PINES	915	21.1%	0.5%	81.1%	-1.1%	0.5%	-1.0%	34.3%	-2.4%	16.1%	1.0%	27.4%	-0.4%	4.1%	0.3%	2.2%	1.7%
8	546	MIAMI	1,317	30.8%	6.1%	76.6%	-4.0%	1.7%	-0.1%	20.6%	-7.0%	17.8%	1.1%	30.8%	-0.3%	3.8%	1.1%	4.2%	2.0%
8	548	W PALM BEACH	463	17.1%	3.1%	87.0%	-3.8%	1.8%	-0.6%	35.7%	-5.8%	17.1%	-0.8%	29.6%	-0.4%	7.9%	4.0%	0.5%	0.3%
8	573	N FL/S GA HCS	1,425	19.0%	-1.3%	85.5%	1.5%	2.1%	0.1%	29.3%	-5.4%	15.9%	1.9%	34.8%	2.7%	3.5%	0.0%	3.2%	2.6%
8	672	SAN JUAN	3,255	17.4%	-1.1%	84.3%	1.1%	0.2%	0.0%	42.1%	-5.3%	22.5%	3.0%	17.0%	0.9%	1.8%	0.9%	2.3%	1.8%
8	673	TAMPA	1,742	32.1%	2.4%	71.9%	-2.5%	1.7%	0.2%	24.5%	-4.8%	12.7%	3.1%	30.3%	-0.7%	3.8%	-0.9%	1.7%	1.0%
9	581	HUNTINGTON	310	23.5%	-1.7%	79.8%	0.8%	0.0%	0.0%	18.4%	-3.8%	21.3%	2.2%	31.6%	-1.2%	4.4%	-0.9%	2.6%	1.8%
9	596	LEXINGTON-LEESTO	324	17.2%	0.1%	87.5%	0.1%	1.1%	-0.3%	28.2%	-0.7%	20.1%	0.6%	36.3%	-3.5%	3.3%	1.2%	1.8%	1.5%
9	603	LOUISVILLE	457	25.6%	1.2%	78.6%	-1.8%	2.5%	-0.2%	21.1%	-3.6%	13.9%	2.5%	33.6%	-2.7%	7.7%	0.2%	2.0%	1.5%
9	614	MEMPHIS	682	28.3%	-3.4%	73.8%	3.9%	1.9%	0.1%	18.2%	-0.5%	15.8%	4.9%	29.2%	-1.6%	8.2%	-0.4%	0.9%	0.4%
9	621	MOUNTAIN HOME	318	30.1%	6.2%	73.6%	-6.4%	0.4%	-0.3%	17.1%	-5.0%	16.7%	-2.6%	28.0%	-1.4%	6.9%	-1.9%	2.0%	1.3%

VISN	Station	Station name	N	Percent prescribed any conventional		Percent prescribed any atypical		Percent prescribed clozapine		Percent prescribed olanzapine		Percent prescribed quetiapine		Percent prescribed risperidone		Percent prescribed ziprasidone		Percent prescribed aripiprazole	
				Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from	
				FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003
9	626	VA MID TENN HCS	1,291	27.5%	-1.3%	77.6%	0.0%	2.8%	0.1%	22.6%	-4.0%	20.3%	1.8%	28.8%	0.2%	5.4%	1.8%	1.1%	0.4%
10	538	CHILLICOTHE	668	39.7%	6.1%	72.6%	-6.5%	7.0%	0.6%	16.6%	-2.3%	22.8%	-4.1%	17.9%	-5.4%	4.5%	0.0%	5.2%	3.7%
10	539	CINCINNATI	562	14.4%	-0.1%	89.1%	0.4%	4.7%	1.0%	28.8%	-4.0%	25.3%	-0.5%	22.2%	1.7%	5.4%	-0.5%	6.2%	1.9%
10	541	CLEVELAND-WADE P	2,203	25.4%	0.2%	78.2%	-0.7%	1.5%	-5.3%	30.0%	-2.6%	17.6%	2.0%	25.6%	2.8%	5.5%	1.5%	0.1%	-0.7%
10	552	DAYTON	530	29.3%	9.3%	72.5%	-10.5%	1.6%	0.2%	21.2%	-10.1%	16.2%	0.4%	30.1%	-0.9%	3.4%	-1.2%	0.3%	-0.2%
10	757	COLUMBUS-IOC	459	20.2%	3.5%	84.7%	-3.2%	0.0%	-2.0%	21.2%	-0.7%	30.6%	-2.9%	31.5%	2.5%	4.3%	2.0%	0.3%	-1.0%
11	506	ANN ARBOR HCS	577	25.3%	3.9%	80.8%	-4.6%	5.5%	0.2%	30.8%	-8.3%	10.4%	-1.0%	31.4%	2.3%	2.9%	0.8%	1.6%	1.6%
11	515	BATTLE CREEK	972	25.6%	0.4%	83.5%	-0.7%	4.3%	0.0%	29.9%	-2.9%	17.3%	1.4%	30.9%	-1.3%	2.2%	0.6%	1.4%	0.8%
11	550	ILLIANA HCS DANV	496	25.8%	-0.2%	79.2%	0.0%	1.6%	-0.1%	29.5%	-1.7%	14.6%	1.2%	29.5%	-2.3%	4.1%	2.3%	0.7%	0.7%
11	553	DETROIT VAMC	1,109	24.8%	4.2%	78.7%	0.4%	4.2%	-0.4%	18.1%	-7.4%	12.7%	0.0%	44.1%	1.5%	0.7%	0.2%	1.8%	1.5%
11	583	INDIANAPOLIS-10T	543	23.3%	3.3%	83.3%	0.3%	2.6%	-0.1%	29.1%	-1.7%	18.7%	4.2%	28.0%	-0.9%	10.0%	0.6%	0.2%	-0.2%
11	610	NORTHERN INDIANA	623	29.8%	-1.0%	75.6%	1.2%	1.3%	-0.2%	25.7%	-8.1%	14.0%	4.5%	37.1%	6.5%	1.7%	-0.8%	0.6%	0.4%
11	655	SAGINAW	346	25.6%	1.2%	81.7%	0.5%	2.1%	-0.2%	20.1%	-4.7%	20.4%	3.5%	34.6%	-3.4%	4.2%	3.8%	2.4%	2.4%
12	537	VA CHICAGO HCS	1,271	17.8%	2.1%	84.5%	-2.1%	0.7%	-0.1%	22.4%	-4.7%	19.0%	1.6%	38.6%	0.4%	3.3%	0.3%	2.0%	0.2%
12	556	NORTH CHICAGO	332	22.5%	1.2%	81.3%	-0.3%	1.9%	-0.6%	24.0%	-8.2%	13.4%	2.1%	29.8%	-2.4%	8.4%	4.2%	2.3%	1.0%
12	578	HINES	620	15.5%	-0.5%	88.4%	1.2%	1.4%	-0.3%	28.4%	1.0%	19.4%	2.7%	39.4%	-2.8%	5.4%	1.5%	2.1%	2.0%
12	585	IRON MOUNTAIN	171	31.1%	-0.6%	81.5%	-1.7%	1.3%	0.0%	24.5%	-1.8%	15.2%	-4.4%	47.0%	1.1%	2.6%	-0.1%	0.0%	0.0%
12	607	MADISON	304	14.9%	-2.2%	87.4%	2.5%	13.4%	-1.8%	26.3%	-2.0%	18.3%	2.4%	23.3%	-0.7%	2.3%	-0.4%	8.4%	4.1%
12	676	TOMAH	293	23.0%	-1.9%	83.1%	3.4%	9.2%	-0.2%	24.9%	-2.9%	8.0%	-1.3%	36.8%	2.1%	3.1%	1.3%	4.6%	3.9%
12	695	MILWAUKEE	703	29.1%	2.8%	78.0%	-1.6%	4.4%	0.1%	21.8%	-1.8%	17.4%	0.2%	31.1%	0.1%	5.2%	-0.3%	3.2%	1.2%
15	589	VAMC HEARTLAND-V	1,976	23.4%	2.1%	82.5%	-2.3%	2.6%	-0.2%	20.3%	-5.2%	21.0%	1.7%	33.0%	-0.4%	7.5%	2.0%	1.8%	0.1%
15	657	VA HEARTLAND-E V	1,925	27.9%	1.6%	81.5%	-0.3%	1.3%	-0.1%	31.7%	-2.2%	19.6%	2.0%	29.7%	-1.4%	3.7%	0.8%	1.9%	1.6%
16	502	ALEXANDRIA	610	16.9%	2.4%	87.0%	-3.9%	3.7%	0.7%	30.6%	-12.8%	18.7%	5.5%	34.9%	-1.4%	3.0%	1.2%	2.6%	1.9%
16	520	GULF COAST HCS	1,383	21.7%	-3.3%	83.0%	-0.8%	0.9%	0.1%	8.1%	-20.7%	28.3%	6.3%	40.1%	5.1%	4.2%	1.8%	2.0%	1.9%
16	564	FAYETTEVILLE AR	391	24.0%	6.4%	80.8%	-7.1%	1.9%	0.5%	20.8%	-6.9%	22.1%	0.1%	29.7%	-0.1%	6.0%	-1.4%	7.9%	4.2%
16	580	HOUSTON	1,423	18.2%	0.7%	86.8%	0.9%	2.1%	0.1%	25.8%	-3.6%	20.2%	2.0%	34.0%	-0.2%	6.3%	1.4%	3.7%	2.2%
16	586	JACKSON	627	17.9%	1.2%	85.1%	-2.4%	0.8%	-0.1%	24.9%	-3.6%	23.4%	0.7%	31.1%	-0.4%	7.2%	0.1%	0.0%	-0.9%
16	598	LITTLE ROCK	735	26.0%	5.0%	78.2%	-4.8%	4.8%	-0.5%	19.2%	-3.4%	15.4%	0.0%	30.7%	-4.3%	6.3%	1.9%	3.7%	0.9%
16	623	MUSKOGEE	379	17.4%	1.4%	86.3%	-0.8%	2.2%	-0.3%	29.5%	-4.3%	20.5%	0.3%	34.2%	3.2%	2.2%	-2.4%	4.3%	4.3%
16	629	NEW ORLEANS	996	21.4%	9.1%	83.5%	-7.1%	0.2%	-0.1%	25.6%	-6.7%	18.2%	4.8%	35.9%	-4.0%	6.2%	-1.8%	1.8%	1.5%
16	635	OKLAHOMA CITY	664	24.2%	4.4%	80.3%	-3.5%	0.2%	-0.2%	25.5%	-6.9%	22.2%	2.5%	31.3%	0.3%	2.0%	0.1%	0.9%	0.7%
16	667	SHREVEPORT	568	24.2%	0.6%	78.5%	0.3%	0.4%	-0.2%	17.0%	-3.9%	17.6%	-1.0%	33.3%	1.7%	7.1%	-0.4%	6.9%	4.3%
17	549	DALLAS	1,426	13.9%	-1.3%	89.4%	0.9%	3.7%	0.1%	29.7%	-7.3%	24.6%	0.7%	26.0%	1.5%	5.2%	1.4%	4.4%	3.2%
17	671	SAN ANTONIO	1,015	21.5%	0.1%	83.7%	0.3%	1.9%	0.0%	26.3%	-3.0%	14.7%	2.7%	32.9%	-2.6%	7.6%	0.7%	3.6%	0.6%
17	674	VA CENTRAL TEXAS	1,247	14.1%	1.2%	89.1%	-0.7%	4.0%	0.3%	28.4%	-7.3%	21.7%	3.2%	34.6%	1.3%	1.8%	-0.5%	1.5%	0.8%
18	501	NEW MEXICO HCS	543	13.6%	-0.4%	88.1%	-0.3%	3.2%	0.7%	19.2%	-5.5%	18.9%	0.4%	34.2%	1.0%	5.6%	-2.0%	9.0%	4.7%
18	504	AMARILLO HCS	181	45.5%	6.3%	58.4%	-8.4%	0.6%	0.0%	11.7%	-7.2%	20.1%	-3.5%	21.4%	0.5%	1.9%	0.6%	2.6%	1.2%
18	519	WEST TEXAS HCS	192	14.4%	-1.3%	86.9%	-1.4%	0.0%	-0.7%	42.5%	-1.9%	20.0%	0.4%	23.8%	-0.4%	1.3%	0.6%	3.8%	3.8%
18	644	PHOENIX	858	23.0%	-0.2%	82.5%	-0.7%	2.3%	0.5%	24.7%	-2.4%	14.9%	2.8%	31.7%	-6.8%	7.3%	3.2%	1.3%	0.4%
18	649	NORTHERN ARIZONA	230	21.1%	-0.9%	84.3%	2.6%	0.0%	0.0%	21.1%	-3.9%	21.1%	4.0%	38.0%	0.8%	3.0%	1.8%	2.4%	0.6%
18	678	SOUTHERN ARIZONA	458	10.2%	0.6%	90.8%	-0.9%	1.6%	0.5%	33.5%	-1.0%	18.1%	-0.9%	34.0%	-2.9%	5.0%	0.0%	6.3%	3.9%
18	756	EL PASO HCS	277	28.8%	1.7%	76.6%	0.4%	0.0%	0.0%	29.3%	-1.9%	10.7%	-0.7%	23.4%	-4.6%	12.7%	6.7%	1.0%	0.1%
19	436	FORT HARRISON	236	17.7%	2.6%	87.2%	1.4%	2.5%	1.5%	30.5%	-3.9%	26.1%	6.4%	28.1%	-3.6%	3.9%	1.2%	3.9%	3.0%
19	442	CHEYENNE	133	22.5%	-3.0%	82.5%	0.7%	0.0%	-0.9%	28.3%	-8.9%	20.8%	2.7%	21.7%	-3.8%	4.2%	-2.2%	10.8%	8.1%
19	554	DENVER	889	25.8%	-2.0%	79.2%	1.3%	4.9%	-0.2%	26.2%	-5.5%	17.1%	2.9%	28.2%	2.1%	4.6%	2.0%	2.6%	0.9%
19	575	GRAND JUNCTION	161	32.9%	5.2%	81.4%	-1.5%	0.7%	0.0%	24.3%	-2.0%	16.4%	1.5%	37.1%	-5.4%	0.0%	-1.4%	5.0%	3.6%
19	660	SALT LAKE CITY H	477	14.0%	-0.4%	91.2%	1.0%	8.8%	-1.0%	35.1%	-2.7%	21.8%	5.9%	24.6%	-1.5%	3.3%	-1.6%	0.0%	-1.0%
19	666	SHERIDAN	153	14.8%	1.4%	90.8%	0.9%	2.8%	-1.2%	39.4%	-8.9%	23.2%	9.1%	29.6%	3.4%	0.7%	-0.6%	9.9%	1.1%
20	463	ALASKA HCS & RO	89	7.7%	-5.4%	93.6%	3.7%	1.3%	-0.2%	55.1%	-8.6%	7.7%	3.3%	24.4%	7.0%	5.1%	2.2%	3.8%	3.8%
20	531	BOISE	286	24.9%	3.6%	80.7%	-3.6%	3.6%	0.4%	16.1%	-2.0%	22.5%	-3.6%	34.1%	-0.4%	5.6%	0.8%	0.4%	-0.4%
20	648	PORTLAND	882	23.5%	1.1%	78.6%	-1.1%	5.3%	-0.7%	23.8%	-3.8%	22.1%	1.5%	15.2%	-2.0%	6.9%	0.0%	7.8%	3.7%
20	653	VA ROSEBURG HCS	353	20.3%	2.8%	84.9%	-1.6%	1.9%	0.7%	22.2%	-6.0%	19.9%	-2.1%	32.8%	1.8%	5.1%	1.2%	7.4%	3.7%
20	663	PUGET SOUND HCS	1,266	19.1%	-0.2%	84.7%	0.0%	2.6%	-0.5%	26.5%	-1.9%	16.7%	0.2%	30.1%	-1.5%	6.8%	0.9%	5.2%	2.8%
20	668	SPOKANE	251	9.8%	0.9%	93.0%	0.4%	1.4%	0.9%	27.6%	-2.1%	27.1%	1.9%	33.2%	-4.0%	6.1%	1.6%	3.7%	1.3%
20	687	WALLA WALLA	154	27.8%	-2.7%	77.8%	0.4%	0.8%	0.0%	27.0%	2.8%	11.1%	-3.0%	32.5%	-6.5%	0.0%	-0.8%	7.1%	7.1%
20	692	WHITE CITY	247	16.7%	0.8%	89.2%	1.0%	1.0%	0.1%	27.6%	-2.0%	26.1%	7.9%	25.1%	-11.7%	8.9%	1.6%	9.4%	7.5%

VISN	Station	Station name	N	Percent prescribed any conventional		Percent prescribed any atypical		Percent prescribed clozapine		Percent prescribed olanzapine		Percent prescribed quetiapine		Percent prescribed risperidone		Percent prescribed ziprasidone		Percent prescribed aripiprazole	
				Change from		Change from		Change from		Change from		Change from		Change from		Change from		Change from	
				FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003	FY 2004	FY 2003
21	358	MANILA	16	44.4%	-17.4%	55.6%	-11.4%	0.0%	0.0%	11.1%	-12.6%	22.2%	11.4%	11.1%	-21.3%	0.0%	0.0%	0.0%	0.0%
21	459	HONOLULU	518	19.5%	-1.3%	83.9%	1.1%	1.8%	0.0%	29.6%	-2.8%	23.0%	1.6%	27.7%	1.1%	7.5%	2.3%	2.2%	1.1%
21	570	CENTRAL CALIFORN	352	15.4%	-2.9%	86.3%	2.6%	0.0%	-2.3%	37.5%	-3.9%	21.1%	2.7%	26.8%	3.4%	2.0%	0.0%	0.7%	0.3%
21	612	NCHC MARTINEZ	1,066	18.7%	-1.0%	86.3%	1.2%	2.5%	0.2%	38.1%	-6.9%	19.2%	2.8%	26.8%	2.8%	3.0%	2.0%	0.4%	0.2%
21	640	PALO ALTO-PALO A	1,034	17.8%	3.2%	87.3%	-3.0%	5.6%	0.2%	44.2%	-4.9%	16.8%	1.7%	22.3%	-0.9%	2.5%	0.5%	2.5%	1.1%
21	654	SIERRA NEVADA HC	259	14.4%	1.8%	90.9%	-0.3%	1.0%	0.4%	27.4%	-8.3%	30.8%	13.2%	27.4%	-1.2%	6.3%	-4.7%	4.3%	4.3%
21	662	SAN FRANCISCO	608	21.5%	2.0%	84.4%	-0.4%	1.5%	0.1%	29.6%	-5.1%	17.9%	2.8%	29.0%	-1.4%	5.8%	-0.3%	4.5%	2.0%
22	593	LAS VEGAS	505	14.3%	1.2%	88.4%	-1.5%	1.5%	0.0%	32.8%	-5.2%	29.1%	4.9%	22.8%	-1.4%	4.9%	-0.2%	1.9%	0.5%
22	600	VA LONG BEACH HC	768	23.7%	4.0%	82.5%	-2.3%	3.3%	0.2%	18.3%	-3.1%	22.2%	-1.4%	29.8%	-5.6%	9.8%	4.1%	6.0%	4.5%
22	605	LOMA LINDA	761	21.3%	2.0%	85.0%	-0.3%	2.0%	-0.3%	24.9%	-2.5%	21.4%	-4.9%	30.6%	1.6%	4.6%	2.1%	4.9%	2.6%
22	664	VA SAN DIEGO HCS	998	24.4%	-1.5%	80.0%	0.3%	1.6%	0.0%	15.7%	-0.7%	18.5%	-0.8%	39.8%	-0.5%	4.4%	0.4%	3.6%	2.2%
22	691	GREATER LA HCS	2,416	17.8%	0.3%	84.5%	-0.3%	2.6%	0.2%	19.7%	-1.6%	24.4%	2.8%	35.2%	-3.6%	3.5%	0.3%	2.8%	1.8%
23	437	FARGO	207	15.1%	1.1%	88.3%	-2.2%	5.0%	-0.6%	46.4%	-2.2%	16.8%	-1.1%	19.6%	0.6%	0.6%	-0.6%	2.8%	1.1%
23	438	SIOUX FALLS	251	23.0%	-0.1%	83.8%	-0.1%	5.4%	0.3%	23.4%	-6.1%	22.5%	6.9%	34.2%	0.1%	3.6%	-1.9%	1.4%	0.9%
23	568	FORT MEADE	222	29.9%	-1.0%	75.6%	-2.3%	4.1%	0.8%	13.2%	-2.3%	32.0%	6.2%	31.5%	-4.7%	3.6%	1.7%	0.5%	-1.4%
23	618	MINNEAPOLIS	890	14.8%	-0.5%	88.4%	0.3%	4.3%	0.2%	34.5%	-5.1%	17.2%	-0.3%	25.2%	1.6%	6.9%	1.0%	3.5%	2.7%
23	636	VA NEB-WESTERN I	1,339	25.0%	2.8%	80.5%	-2.4%	3.7%	0.3%	26.5%	-3.3%	15.6%	-1.3%	29.4%	-0.7%	5.8%	0.6%	4.3%	3.0%
23	656	ST CLOUD	303	19.4%	-4.0%	85.6%	3.2%	8.6%	0.5%	46.4%	-2.1%	14.0%	2.8%	15.8%	0.9%	1.4%	0.1%	1.8%	1.8%
Min				7.7%	-17.4%	55.6%	-11.4%	0.0%	-6.4%	8.1%	-20.7%	7.7%	-4.9%	11.1%	-21.3%	0.0%	-4.7%	0.0%	-1.4%
Max				45.5%	9.3%	93.6%	4.1%	13.4%	1.5%	55.1%	5.9%	32.0%	13.2%	49.2%	7.7%	16.6%	6.7%	10.8%	8.1%
Mean			719	23.2%	0.7%	81.6%	-0.9%	2.5%	-0.2%	25.7%	-4.3%	19.1%	1.6%	29.9%	-0.9%	4.7%	0.5%	3.1%	2.0%
Std. Dev.			549	6.9%	3.1%	6.2%	2.7%	2.3%	0.9%	7.3%	3.1%	4.9%	3.0%	6.2%	3.5%	2.7%	1.6%	2.5%	1.9%
Coeff. of Var.			0.76	0.30	-7.7%	0.08	13.0%	0.92	3.0%	0.28	11.9%	0.25	-9.4%	0.21	3.1%	0.58	-8.2%	0.80	-27.8%